Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
uniQure N.V. (QURE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs"
08/01/2023 8-K Quarterly results
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/16/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "uniQure Announces Sale of Royalty Interest in HEMGENIX for Up To $400 Million"
05/09/2023 8-K Quarterly results
Docs: "uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress"
04/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "uniQure Announces 2022 Financial Results and Highlights Recent Company Progress"
01/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1"
12/16/2022 8-K Quarterly results
11/28/2022 8-K Quarterly results
11/23/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
03/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’ s Disease"
02/25/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "uniQure Announces 2021 Financial Results and Highlights Recent Company Progress"
02/08/2022 8-K Quarterly results
02/04/2022 8-K Quarterly results
12/28/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
12/17/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease"
12/13/2021 8-K Quarterly results
10/25/2021 8-K Quarterly results
Docs: "uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress"
10/21/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/30/2021 8-K Quarterly results
07/27/2021 8-K Quarterly results
Docs: "uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress"
06/23/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
05/21/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
04/26/2021 8-K Quarterly results
04/22/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy